US-based assay developer Essen BioScience has introduced the live-cell analysis platform ‘IncuCyte S3’ to enable automated measurements of cell health, proliferation, movement and function directly inside a standard incubator.
The IncuCyte S3 can be utilised for real-time live-cell analysis, along with automated data capture and cell assessment, to provide new insights and understanding into biological processes and cellular function.
The platform will facilitate continuous monitoring of cells, collection of accurate data and scheduling of regular sampling intervals for days, weeks or months.
IncuCyte S3 platform comprises instrumentation, reagents, consumables and analytical software for kinetic, image-based measurements.
Essen BioScience president and chief executive officer Brett Williams said: “The IncuCyte S3 platform represents a transformative approach to live-cell analysis, enabling researchers to conceive of and execute experiments that were not previously thought possible and answer new types of questions.”
The system and reagents are claimed to not disturb the cell health and morphology, resulting in minimum potential artifacts in user experiments.
The platforms’ interface enables use of different applications by multiple users and the data can be accessed remotely through unlimited, free networked licences.
It offers an option to fit multiple T-flasks or up to six 96 or 384 well microtiter plates for enhanced productivity and simultaneous use of various applications and assays.
The system collects more than 4,000 images per hour in a kinetic format allowing study of cell behaviours such as movement, migration and apoptosis.
Sartorius Group has acquired Essen from SFW Capital Partners for $320m.
Image: IncuCyte S3 live-cell analysis platform. Photo: courtesy of PRNewsFoto/Essen BioScience.